CEO
Dr. Vegesna brings over 35 years of pharmaceutical experience. In the early part of his career, for the first 15 years, He worked for companies such as GSK, BASF, and Johnson & Johnson (McNeil Consumer Products), most notably in formulation development, product development, Technology Transfer, manufacturing, and compliance. He co-founded LiquiSource Inc (2001-2003) and Allan Pharmaceutical Inc (2004-2008). He joined the senior management team of VersaPharm Inc (a Georgia-based company that acquired Allan Pharmaceuticals) in 2008 and developed several ANDAs. In 2014, VersaPharm was successfully sold to Akorn, Inc. In 2017, He co-founded Douglas Pharma US Inc in affiliation
with Douglas Pharmaceuticals, a New Zealand-based company. He developed several As for US markets for the last four years and managed several successful US FDA
inspections.
Dr. Vegesna holds an MS in Pharmacy from Andhra University, India, and an MS and Ph.D. in Pharmaceutical Sciences from the University of British Columbia, Vancouver, Canada.
Advisor and Board of Directors
Mr. Connolly brings over 30 years of finance and management experience in Pharmaceuticals. Notably, He was the CFO for Taro Pharmaceuticals for 13 years where he increased the market cap from $25 million to $2.5 billion. He Co-founded VersaPharm Inc in 2006 by partnering with TailWind Investment Group. Under his leadership as CEO, He grew the company and successfully sold it to Akorn Inc in 2014 for 440 million. In 2017, He partnered with Dr. Raju Vegesna and co-founded Douglas Pharma US, Inc as an affiliate of Douglas Pharmaceuticals, a New Zealand-based parent company. Under his leadership as President from 2017 to 2021, he established a prominent US presence for Douglas.
He has been on board with a few other pharmaceutical companies and investment groups. Kevin is a graduate of Fordham University and holds a CPA.
Vice President
Nandu has a degree in Mechanical Engineering and a diploma in AutoCAD drawings. He brings close to 27 years of pharmaceutical experience mainly in the building, maintenance, and Pharmaceutical Operations of Injectable facilities. He started his career with Dr.Reddy’s in 1994 and worked for 10 years. He moved to the US in 2004 and worked for Inva-Gen (NY), SunPharma (NJ), and AuroLife (NJ) with increasing responsibilities in the area of Engineering and Project management. He joined Penn Life Sciences (PA) in 2012 and worked as a Plant Head till March 2022. He has been credited as being responsible for building at least 3 state of the art injectable facilities from the scratch in the Northeastern Region. He interacted with FDA in presenting facility concepts and documentation. He faced multiple audits with FDA over the years.